NASDAQ:OTICOtonomy Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Otonomy Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.72 -0.04 (-1.45 %) (As of 06/3/2020 04:00 PM ET) Add Compare Share Today's Range$2.65Now: $2.72▼$2.7950-Day Range$2.00MA: $2.35▼$2.6852-Week Range$1.53Now: $2.72▼$4.18Volume57,001 shsAverage Volume72,297 shsMarket Capitalization$83.97 millionP/E RatioN/ADividend YieldN/ABeta2.32 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase I/II clinical trial to treat tinnitus; and OTO-413, a proprietary formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, a sustained-exposure formulation of small molecule otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingOtonomy has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Otonomy has a potential upside of 194.1% from its current price of $2.72.Amount of Analyst CoverageOtonomy has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesOtonomy has received 314 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOtonomy has received 306 “underperform” votes. (Add your “underperform” vote.)Community SentimentOtonomy has received 50.65% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Otonomy and other stocks. Vote “Outperform” if you believe OTIC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OTIC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOtonomy does not currently pay a dividend.Dividend GrowthOtonomy does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Otonomy insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 11.70% of the stock of Otonomy is held by insiders.Percentage Held by Institutions58.13% of the stock of Otonomy is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Otonomy are expected to grow in the coming year, from ($1.41) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Otonomy is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Otonomy is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOtonomy has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.53 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OTIC Previous Symbol CUSIPN/A CIK1493566 Webwww.otonomy.com Phone619-323-2200Debt Debt-to-Equity Ratio0.96 Current Ratio4.44 Quick Ratio4.44Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$600,000.00 Price / Sales139.94 Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book2.08Profitability EPS (Most Recent Fiscal Year)($1.45) Net Income$-44,670,000.00 Net Margins-7,826.41% Return on Equity-98.90% Return on Assets-51.41%Miscellaneous Employees49 Outstanding Shares30,870,000Market Cap$83.97 million Next Earnings Date8/6/2020 (Estimated) OptionableOptionable NASDAQ:OTIC Rates by TradingView Receive OTIC News and Ratings via Email Sign-up to receive the latest news and ratings for OTIC and its competitors with MarketBeat's FREE daily newsletter. Otonomy (NASDAQ:OTIC) Frequently Asked Questions How has Otonomy's stock been impacted by COVID-19 (Coronavirus)? Otonomy's stock was trading at $2.62 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OTIC stock has increased by 3.8% and is now trading at $2.72. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Otonomy? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Otonomy. When is Otonomy's next earnings date? Otonomy is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Otonomy. How were Otonomy's earnings last quarter? Otonomy Inc (NASDAQ:OTIC) announced its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.02. The biopharmaceutical company earned $0.16 million during the quarter. Otonomy had a negative return on equity of 98.90% and a negative net margin of 7,826.41%. View Otonomy's earnings history. What price target have analysts set for OTIC? 3 analysts have issued 1-year target prices for Otonomy's stock. Their forecasts range from $8.00 to $8.00. On average, they expect Otonomy's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 194.1% from the stock's current price. View analysts' price targets for Otonomy. Has Otonomy been receiving favorable news coverage? News articles about OTIC stock have trended very positive on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Otonomy earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutOtonomy. Are investors shorting Otonomy? Otonomy saw a decline in short interest in May. As of May 15th, there was short interest totaling 137,800 shares, a decline of 14.1% from the April 30th total of 160,400 shares. Based on an average daily volume of 134,900 shares, the days-to-cover ratio is currently 1.0 days. Approximately 0.6% of the company's stock are short sold. View Otonomy's Current Options Chain. Who are some of Otonomy's key competitors? Some companies that are related to Otonomy include Kamada (KMDA), Selecta Biosciences (SELB), Wave Life Sciences (WVE), Rigel Pharmaceuticals (RIGL), Urovant Sciences (UROV), Osmotica Pharmaceuticals (OSMT), Geron (GERN), Humanigen (HGEN), OrganiGram (OGI), Bicycle Therapeutics (BCYC), TherapeuticsMD (TXMD), Verastem (VSTM), MannKind (MNKD), Avadel Pharmaceuticals (AVDL) and Lannett (LCI). View all competitors. What other stocks do shareholders of Otonomy own? Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include Canaccord Genuity (), BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird () and Wellington Shields (). Who are Otonomy's key executives? Otonomy's management team includes the following people: Dr. Jay B. Lichter, Co-Founder & Chairman (Age 57)Dr. David Allen Weber, Pres, CEO & Director (Age 59)Mr. Paul E. Cayer, Chief Financial & Bus. Officer (Age 57)Mr. Robert Michael Savel II, Chief Technical Officer (Age 51)Dr. Allen F. Ryan Ph.D., Co-Founder and Member of the Advisory Panel What is Otonomy's stock symbol? Otonomy trades on the NASDAQ under the ticker symbol "OTIC." Who are Otonomy's major shareholders? Otonomy's stock is owned by a number of institutional and retail investors. Top institutional investors include First Manhattan Co. (3.26%), BlackRock Inc. (2.58%), Granahan Investment Management Inc. MA (0.54%), Acadian Asset Management LLC (0.52%), Mercer Global Advisors Inc. ADV (0.29%) and Orbimed Advisors LLC (0.23%). View institutional ownership trends for Otonomy. Which institutional investors are selling Otonomy stock? OTIC stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co., Orbimed Advisors LLC, Mercer Global Advisors Inc. ADV, and BlackRock Inc.. View insider buying and selling activity for Otonomy. Which institutional investors are buying Otonomy stock? OTIC stock was acquired by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, Acadian Asset Management LLC, Connor Clark & Lunn Investment Management Ltd., Ensign Peak Advisors Inc, and JPMorgan Chase & Co.. View insider buying and selling activity for Otonomy. How do I buy shares of Otonomy? Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Otonomy's stock price today? One share of OTIC stock can currently be purchased for approximately $2.72. How big of a company is Otonomy? Otonomy has a market capitalization of $83.97 million and generates $600,000.00 in revenue each year. The biopharmaceutical company earns $-44,670,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. Otonomy employs 49 workers across the globe. What is Otonomy's official website? The official website for Otonomy is www.otonomy.com. How can I contact Otonomy? Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected] This page was last updated on 6/4/2020 by MarketBeat.com Staff
